Food for thought:
Sarepta was a US $60 million Coy.
After their phase 2 they went to $6 billion MC
Anp is similar .. hardly any interest..
however when you look at the RISK REWARD Itsa scratches his head..$$
Sarepta entering into P2 was a one trick pony
Anp not only going into P2+ have proved
the end points in P2 going into P2+
Have multiple other indications to fall back on eg
Fibrosis. Neuromuscular and Neurodegenerative
diseases etc.
Sarepta did not have the backing of the FDA and still don’t…
Anp on the other hand has the backing of the FDA and was asked to file for FastTrack. Designation.
Food for thought:Sarepta was a US $60 million Coy.After their...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.5¢ |
Change
-0.002(2.30%) |
Mkt cap ! $76.63M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 8.7¢ | 8.5¢ | $12.66K | 146.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 197135 | 8.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.7¢ | 329525 | 1 |
View Market Depth
| Last trade - 10.14am 02/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |